Immune checkpoint blockade is presented as a major cancer immunotherapy theme in the review, especially around CTLA-4 and PD-1/PD-L1 biology and clinical practice.
First-pass extracted concept
immune checkpoint blockade
Candidate: concept label3 source documents3 linked claims
Live refresh every 5sNext refresh in 5s
Aliases
checkpoint blockade
Extracted Explainers
What the tool is doing
What problem it solves
What it does not solve
Evidence Snippets
We discuss emerging strategies aimed at overcoming these obstacles, such as combinatorial antigen targeting, immune checkpoint blockade, synthetic biology tools, and gene editing technologies.
Finally, we outline future directions: logic-gated CARs, iPSC-derived NK platforms, and combinatorial approaches with immune checkpoint blockade.
The supplied source summary explicitly states that the review spans CTLA-4/PD-1 checkpoint blockade and clinical translation.
Supporting Sources
Linked Claims
Emerging strategies to overcome solid-tumor barriers in T cell immunotherapy include combinatorial antigen targeting, immune checkpoint blockade, synthetic biology tools, and gene editing technologies.
Quoted textsource-backed
We discuss emerging strategies aimed at overcoming these obstacles, such as combinatorial antigen targeting, immune checkpoint blockade, synthetic biology tools, and gene editing technologies.
Future directions in engineered NK therapy include logic-gated CARs, iPSC-derived NK platforms, and combinations with immune checkpoint blockade.
This review synthesizes cancer immunotherapy from T-cell basic science through clinical practice, including checkpoint blockade, adoptive cellular therapy, CAR-T, and neoantigen-directed approaches.